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ABSTRACT
O-CholesteryI-O-phenyI-N-phenylphosphoramidate (1) and four organotin (IV) derivatives of
the ambidentate O-cholesteryI-O-phenyl phosphorothioate ligand formulated as Me3SnOSPR’R"(2),
Ph3SnOSPR’R"(3), O(CH2CHS)Sn(n-Bu)OSPR’R"(4), S(CHCHS)2Sn(n-Bu)OSPR’R"(5), (R’= O-
phenyl; R"= O-cholesteryl) were subjected to cytotoxicity screening against KB (nasopharingel
carcinoma), OVCAR-5 (ovarium carcinoma) and SQC-1 UISO (squamous cell cervix carcinoma)
cell cultures. The results of the bioassay showed that these compounds possess potent antitumor
activities against the studied human carcinoma cell lines.
INTRODUCTION
Phosphoramidates have considerable biological interest as anticancer agents [1], and have
been widely used, according to the scheme [2], in the synthesis of organophosphates,
phosphorothioates and phosphoroselenoates. We have prepared and structural characterized the
two epimeric of O-CholesteryI-O-phenyI-N-phenylphosphoramidates (1), that were used for the
preparation of a new ambidentate phosphorothioate ligand containg a O-cholesteryl residue [3].
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Scheme 1: Synthesis of phosphates, phosphorothioates and phosphoroselenoates.
The organotin derivatives with natural products have received considerable impulse by
inorganic and organometallic chemist for diverse reasons, including the potential bioactivity. The
organotin(IV) derivatives with steroids exhibit biological activities (especially antitumour) [4-6] and
have been studied with respect to the reactivity and interesting structural features. The structural
chemistry of phosphorus-based organo tin(IV) derivatives is influenced by the number and nature of
organic groups bonded to tin and phosphorus atoms, as well as the type of donor atom (O, S, Se)
[7]. Recently, we have reported the preparation of a new ambidentate phosphorothioate ligand,
containing a bioactive group, Na[OSPR’R"], [R’= O-Phenyl, R"= O-cholesteryl] [8], that was used for
the synthesis of four organometallic tin (IV) (2-5) [9]. In this paper, we report the results of the
bioassay of compounds (1-5), showing that they posses potent antitumor activities against KB
(nasopharyngel carcinoma), OVCAR-5 (ovarium carcinoma) and SQC-1 UISO (squamous cell
cervix carcinoma).
MATERIALS AND METHODS
Preparation and spectroscopic features of the pure compounds tested in this work (1-5) were
reported previously [3, 9], they were characterized by elemental analyses, IR, MS and multinuclear
NMR (H, C, P, Sn) spectroscopy. The structures of these compounds are shown in scheme 2.
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Scheme 2: O-cholesteryI-O-phenyI-N-phenylphosphoramidate (1) and the four Organotin (IV)
derivatives of the ambidentate O-cholesteryI-O-phenyl phosphorothioate ligand (2-5).
Evaluation of Biological Activity. Cytotoxic Activity.
The KB (nasopharyngel carcinoma), Ovcar-5 (ovarium carcinoma), and SQC-1 UISO
(squamous cell cervix carcinoma) cell lines were maintained in BME (Basal Medium Eagle) with
10% fetal bovine serum (FBS). All cell lines were cultured at 37 C in an atmosphere of 5% CO2 in
air (100% humidity).
The cells at a log phase of their growth cycle were treated in triplicate at various
concentrations of the pure compounds to evaluate (0.5-100 pg/ml), and incubated for 72 h at 37 C
in a humidified atmosphere of 5 % CO2. The cell concentration was determined by protein analysis.
Results were expressed as the dose that inhibits 50% control growth after the incubation period
(EDs0). The values were estimated from a semilog plot of the drug concentration (pg/ml) against the
percent of viable cells. Pure compounds with EDs0 4 rtg/ml were considered active according to
National Cancer Institute (NCI) guidelines described in the literature [10] (Geran et al., 1972).
RESULTS AND DISCUSSION.
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Cytotoxic Activities
Table 1 shows the cytotoxic data of the tested pure compounds (1-5). This compounds
containing O-cholesteryl, show significant cytotoxic activity towards SQC-1 UISO cell line (EDo
values 1.7, <1, <1, 1.5, <1 tag/mL, respectively). They also showed a moderate toxicity against KB
cell line (EDo values 3.3, >4, 2.7, 3.1, 2.8 tag/mL, respectively) and significant and moderate
cytotoxic activity against the Ovcar-5 cell line (ED0 values <1, <1,2.9, 2.8, >4 tg/mL, respectively).
According to these results, the five compounds exhibited important cytotoxic activities against
the tested cell lines in culture. From the three studied cell lines, the cervix carcinoma SQC-1 UISO
was the most sensitive to the action of the compounds under investigation. Compound 2 displayed
an important toxic activity against SQC-1 UISO and OVCAR-5, and was inactive toward the
nasopharyngel carcinoma KB. In conclusion the results showed that compounds 1-5 presented
cytotoxic action towards the studied cell lines.
Table 1. Cytotoxicity of pure compounds (EDso (lg/ml)) PhNH(O)PR’R" (1), Me3SnOSPR’R" (2),
Ph3SnOSPR’R" (3), O(CH2CH2S)2Sn(n-Bu)OSPR’R" (4), S(CH2CH2S)2Sn(n-Bu)OSPR’R" (5). [R’=
O-Ph, R"= O-cholesteryl].
ED0 values (lglml)
Cell line
Compounds KB SQC-1 UlSO OVCAR-5
(1)PhNH(O)PR’R" 3.3 1.7 < 1
(2) Me3SnOSPR’R" > 4 < 1 < 1
(3) Ph3SnOSPR’R" 2.7 < 1 2.9
(4) O(CH2CH2S)2Sn(nBu)OSPR’R" 3.1 1.5 2.8
(5)S(CHCHS)2Sn(nBu)OSPR’R" 2.8 < 1 > 4
Antitumoragents (controls):
c01chicine < 1 1.58 < 1
Ellipticine 1.58 1.77 0.6
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